NKGN vs. CRTX, PLUR, SRZN, INKT, TARA, BCLI, ACHL, AIM, ZIVO, and EVAX
Should you be buying NKGen Biotech stock or one of its competitors? The main competitors of NKGen Biotech include Cortexyme (CRTX), Pluri (PLUR), Surrozen (SRZN), MiNK Therapeutics (INKT), Protara Therapeutics (TARA), Brainstorm Cell Therapeutics (BCLI), Achilles Therapeutics (ACHL), AIM ImmunoTech (AIM), ZIVO Bioscience (ZIVO), and Evaxion Biotech A/S (EVAX). These companies are all part of the "medical" sector.
Cortexyme (NASDAQ:CRTX) and NKGen Biotech (NYSE:NKGN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, community ranking, profitability, valuation and risk.
63.2% of Cortexyme shares are owned by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are owned by institutional investors. 27.9% of Cortexyme shares are owned by insiders. Comparatively, 20.0% of NKGen Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Cortexyme received 154 more outperform votes than NKGen Biotech when rated by MarketBeat users.
In the previous week, NKGen Biotech had 1 more articles in the media than Cortexyme. MarketBeat recorded 1 mentions for NKGen Biotech and 0 mentions for Cortexyme. NKGen Biotech's average media sentiment score of 0.00 equaled Cortexyme'saverage media sentiment score.
NKGen Biotech has higher revenue and earnings than Cortexyme.
Cortexyme has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500. Comparatively, NKGen Biotech has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500.
Cortexyme's return on equity of 0.00% beat NKGen Biotech's return on equity.
Summary
NKGen Biotech beats Cortexyme on 5 of the 9 factors compared between the two stocks.
Get NKGen Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for NKGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NKGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NKGen Biotech Competitors List
Related Companies and Tools
